"Tomala, Jakub" . "21159" . . . . . "Increasing the biological activity of IL-2 and IL-15 through complexing with anti-IL-2 mAbs and Il-15Ralfa-Fc chimera" . . "1" . "RIV/61388971:_____/14:00441077!RIV15-GA0-61388971" . . "IL-2; IL-15; chimera"@en . . . . "195" . . "RIV/61388971:_____/14:00441077" . . "000337018400001" . . . "I, P(ED1.1.00/02.0109), P(GA13-12885S), P(GAP301/11/0325)" . "Votavov\u00E1, Petra" . "Increasing the biological activity of IL-2 and IL-15 through complexing with anti-IL-2 mAbs and Il-15Ralfa-Fc chimera"@en . . . "[F9559E32FAB7]" . "Increasing the biological activity of IL-2 and IL-15 through complexing with anti-IL-2 mAbs and Il-15Ralfa-Fc chimera" . "0165-2478" . "NL - Nizozemsko" . "3"^^ . . "10"^^ . "Immunology Letters" . "IL-2 and IL-15 are structurally relative cytokines that share two receptor subunits, CD132 (-y, chain) and CD122 (beta chain). However, the expression pattern and physiological role of IL-2 and IL-15 private receptor a chains CD25 and IL-15Ra, respectively, are strikingly different. CD25, together with CD122 and CD132, forms a trimeric high affinity IL-2 receptor that is expressed and functions on cells acquiring an IL-2 signal. Conversely, IL-15Ra is expressed and binds IL-15 with high affinity per se already in the endoplasmic reticulum of the IL-15 producing cells and it presents IL-15 to cells expressing CD122/CD132 dimeric receptor in trans. Thus, while IL-2 is secreted almost exclusively by activated T cells and acts as a free molecule, IL-15 is expressed mostly by myeloid cells and works as a cell surface-associated cytokine. Interestingly, the in vivo biological activity of IL-2 can be dramatically increased through complexing with certain anti-IL-2 itiAbs; such IL-2/anti-IL-2 mAbs immunocomplexes selectively stimulate the proliferation of a distinct population of immune cells, depending on the clone of the anti-IL-2 mAb used. IL-2/S4B6 mAb immunocomplexes are highly stimulatory for CD122high populations (memory CD8* T and NK cells) and intermediately also for CD25(high) populations (Treg and activated T cells), while IL-2/JES6-1 mAb immunocomplexes enormously expand only 5high cells. Although IL-2 immunocomplexes are much more potent than IL-2 in vivo, they show comparable to slightly lower activity in vitro. The in vivo biological activity of IL-15 can be dramatically increased through complexing with recombinant IL-15Ra-Fc chimera; however, IL-15/IL-15Ra-Fc complexes are significantly more potent than IL-15 both in vivo and in vitro. In this review we summarize and discuss the features and biological relevance of IL-2/anti-IL-2 mAbs and IL-15/1L-15Ra-Fc complexes, and try to foreshadow their potential in immunological research and immunotherapy."@en . . . . . "3"^^ . "IL-2 and IL-15 are structurally relative cytokines that share two receptor subunits, CD132 (-y, chain) and CD122 (beta chain). However, the expression pattern and physiological role of IL-2 and IL-15 private receptor a chains CD25 and IL-15Ra, respectively, are strikingly different. CD25, together with CD122 and CD132, forms a trimeric high affinity IL-2 receptor that is expressed and functions on cells acquiring an IL-2 signal. Conversely, IL-15Ra is expressed and binds IL-15 with high affinity per se already in the endoplasmic reticulum of the IL-15 producing cells and it presents IL-15 to cells expressing CD122/CD132 dimeric receptor in trans. Thus, while IL-2 is secreted almost exclusively by activated T cells and acts as a free molecule, IL-15 is expressed mostly by myeloid cells and works as a cell surface-associated cytokine. Interestingly, the in vivo biological activity of IL-2 can be dramatically increased through complexing with certain anti-IL-2 itiAbs; such IL-2/anti-IL-2 mAbs immunocomplexes selectively stimulate the proliferation of a distinct population of immune cells, depending on the clone of the anti-IL-2 mAb used. IL-2/S4B6 mAb immunocomplexes are highly stimulatory for CD122high populations (memory CD8* T and NK cells) and intermediately also for CD25(high) populations (Treg and activated T cells), while IL-2/JES6-1 mAb immunocomplexes enormously expand only 5high cells. Although IL-2 immunocomplexes are much more potent than IL-2 in vivo, they show comparable to slightly lower activity in vitro. The in vivo biological activity of IL-15 can be dramatically increased through complexing with recombinant IL-15Ra-Fc chimera; however, IL-15/IL-15Ra-Fc complexes are significantly more potent than IL-15 both in vivo and in vitro. In this review we summarize and discuss the features and biological relevance of IL-2/anti-IL-2 mAbs and IL-15/1L-15Ra-Fc complexes, and try to foreshadow their potential in immunological research and immunotherapy." . "Increasing the biological activity of IL-2 and IL-15 through complexing with anti-IL-2 mAbs and Il-15Ralfa-Fc chimera"@en . "Kov\u00E1\u0159, Marek" .